On a fundamental basis we have nothing new over the last couple of weeks. some moan that amrn has wallowed in the doldrums, lets look what this name has been through:
Silly Italian study
Even sillier prostate cancer study
Lovaza generic scare
Fraudstein/silly summer street short bucket shop.
A lot of WS knows this story very well. They were ther early post Anchor data. the only thing JZ dropped the ball on was saying how mich buyout interest was percolating. How could he know that FDA would never decide on NCE. But a lot of peeps got burned. It will take a bit more greed to get them back.
Given how cash rich and risk averse BP is, we are now coming to another confluence of events. Perhaps there is no NCE coming but anchor and the huge patent moat changes everything versus last time around.
GIA still must be the investment strategy but that looks decent given Lovaza side effects and massive off label use leading to huge easy low hanging fruit.
I love your unbridled enthusiasm but we are not there quite yet. When docs "get it" that Vascepa is better than Lovaza we have some fun ahead. Maybe ADcom helps get there. Maybe PDUFA helps. Not sure what it will take. Clearly mgt knows what they have.maybe buyout price doesn't go up w ADcom but we just don't know. At this point mgt has put the bar super low after last cc saying more about GIA.